# Intermittent Fasting May Enhance Resistance Training Effects on the Body Composition of Obese Males, Without Affecting Muscular Strength and Anabolic Index

**Authors:** Ali Farahmand Khoshkebijari, Maryam Ebrahimi, Abuzar Jorbonian

PMC · DOI: 10.1155/jobe/6409069 · Journal of Obesity · 2026-02-19

## TL;DR

Intermittent fasting combined with resistance training helps obese men lose more weight and fat without harming muscle strength or anabolic hormones.

## Contribution

This study shows intermittent fasting enhances resistance training benefits in obese males without negative effects on strength or anabolic markers.

## Key findings

- The IF/RT group lost twice as much weight and fat compared to the control group.
- No significant difference in muscular strength or testosterone levels between the groups.
- Intermittent fasting did not negatively affect the anabolic index.

## Abstract

This randomized controlled trial aimed to evaluate the impact of intermittent fasting (IF) during resistance training (RT) on body composition, muscular strength, and the testosterone:cortisol ratio in obese males.

Twenty obese males (aged 20–30, BMI 30–36 kg/m2) were selected from eligible volunteers and randomly assigned to control (regular diet) and IF (4:3 IF) groups. All subjects participated in RT 3 days/week for 8 weeks. Forty‐eight hours before and after the protocol, blood sampling and anthropometric measurements were done in a fasting state, and data were analyzed at a significance level of p < 0.05.

The IF/RT group lost twofold more weight and fat, had higher arm and chest measurements, and had less waist circumference than the C/RT group. The testosterone levels and muscle strength improved with RT, and there was no difference between the C/RT and IF/RT groups.

It appears that intermittent fasting may enhance the efficacy of RT in obese males and is unlikely to have any detrimental effects on muscular strength or the anabolic index.

Trial Registration: Iranian Registry of Clinical Trials (IRCT): IRCT20190213042702N4

## Linked entities

- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** overweight (MESH:D050177), LBM (MESH:D013851), musculoskeletal injuries (MESH:D009140), Obese (MESH:D009765), Fat% (MESH:D004620), muscle hypertrophy (MESH:C536106), metabolic syndrome (MESH:D024821), weight loss (MESH:D015431), IF (MESH:D007003), cardiovascular diseases (MESH:D002318), diabetes (MESH:D003920), hypertrophy (MESH:D006984)
- **Chemicals:** lipids (MESH:D008055), Testosterone (MESH:D013739), ketone bodies (MESH:D007657), glucose (MESH:D005947), glycerol (MESH:D005990), ADF (-), triglycerides (MESH:D014280), epinephrine (MESH:D004837), fatty acids (MESH:D005227), catecholamine (MESH:D002395), Cortisol (MESH:D006854)
- **Species:** gut metagenome (species) [taxon 749906], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12917691/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12917691/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12917691/full.md

---
Source: https://tomesphere.com/paper/PMC12917691